Evaluation of the Sedative Activity of Naringenin: In Vivo Study with Pharmacokinetics and Molecular Docking Insights
ChemistryOpen · 2025
DOI: 10.1002/open.202500114 ↗Kurz gefasst
Fachartikel in der Zeitschrift ChemistryOpen, 2025. Verfasst von Dipu Bishwas und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Pabna University of Science and Technology, Pabna, 6600, Bangladesh. Hauptthemen laut MEDLINE: Molecular Docking Simulation, Flavanones, Hypnotics and Sedatives. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deanship of Research and Graduate Studies at King Khalid University.
Abstract (Originalsprache)
This research is designed to investigate the sedative effects of naringenin (NAR) and diazepam against thiopental sodium‐induced sleeping mice. NAR (5 and 10 mg kg), diazepam (DZP) (2 mg kg), flumazenil (FLN) (0.1 mg kg), and their combinations are administered intraperitoneally to mice. After 30 min, sleep is induced with intraperitoneal thiopental sodium (20 mg kg), and sleep latency and duration are measured. In silico analysis investigates the role of GABA receptors. NAR significantly reduces sleep latency and prolongs sleep duration in a dose‐dependent manner, with the combination of NAR‐10 and DZP‐2 showing a synergistic effect. The combination of the antagonist (FLN) (NAR‐10 and FLN‐0.1) indicates that latency increases and sleep duration decreases compared to NAR‐10 alone. Furthermore, in silico docking studies corroborates these results, demonstrating a significant binding affinity of NAR (−8.3 kcal mol), which is comparable to the standard ligand DZP (−8.7 kcal mol) and FLN (−7.0 kcal mol) for the GABA A (6X3X) receptor, indicating a GABAergic mechanism. Pharmacokinetics and toxicity evaluations confirm NAR's potential as a safe therapeutic agent, with a high LD50 (2000 mg kg) and minimal toxicity. These findings highlight NAR's potential as a GABAergic sedative agent, requiring further research before being used clinically to treat sleep disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Pabna University of Science and Technology, Pabna, 6600, Bangladesh.
- Bioinformatics and Drug Innovation Laboratory, Bioluster Research Center Ltd., Gopalganj, 8100, Dhaka, Bangladesh.
- Department of Pharmacy, Gopalganj Science and Technology University, Gopalganj, 8100, Bangladesh.
- Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Khalid University, Abha, 61421, Saudi Arabia.
- Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh, 11451, Saudi Arabia.
- Department of Internal Surgical Nursing, College of Nursing, King Saud University, Riyadh, 11451, Saudi Arabia.
ORCID-Profile: Md Shimul Bhuia, Salehin Sheikh
Förderung
- Deanship of Research and Graduate Studies at King Khalid University
Zitieren
APA
Bishwas, D., Bhuia, M. S., Sheikh, S., Alfaifi, M., Malik, A., Siddiqui, N. J., Jain, D., Bappi, M. H., & Islam, M. T. (2025). Evaluation of the Sedative Activity of Naringenin: In Vivo Study with Pharmacokinetics and Molecular Docking Insights. ChemistryOpen. https://doi.org/10.1002/open.202500114
Vancouver
Bishwas D, Bhuia MS, Sheikh S, Alfaifi M, Malik A, Siddiqui NJ, et al. Evaluation of the Sedative Activity of Naringenin: In Vivo Study with Pharmacokinetics and Molecular Docking Insights. ChemistryOpen. 2025. doi:10.1002/open.202500114
BibTeX
@article{Bishwas2025,
author = {Bishwas, Dipu and Bhuia, Md Shimul and Sheikh, Salehin and Alfaifi, Mohammed and Malik, Abdul and Siddiqui, Nikhat J and Jain, Divya and Bappi, Mehedi Hasan and Islam, Muhammad Torequl},
title = {Evaluation of the Sedative Activity of Naringenin: In Vivo Study with Pharmacokinetics and Molecular Docking Insights},
journal = {ChemistryOpen},
year = {2025},
doi = {10.1002/open.202500114}
}
EUVIMED